Menu Search
Equities

Actinium Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
7AY1:FRA

Actinium Pharmaceuticals Inc

Actions
  • Price (EUR)0.9355
  • Today's Change-0.007 / -0.74%
  • Shares traded400.00
  • 1 Year change-13.22%
  • Beta-0.3045
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.

  • Revenue in USD (TTM)90.00k
  • Net income in USD-34.60m
  • Incorporated2013
  • Employees37.00
  • Location
    Actinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
  • Phone+1 (646) 677-3870
  • Fax+1 (845) 818-3588
  • Websitehttps://www.actiniumpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.